These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 35994263)

  • 21. Organ Donors with Human Immunodeficiency Virus and Hepatitis C Virus: Expanding the Donor Pool.
    Salas J; Storm K; Durand CM
    Infect Dis Clin North Am; 2023 Sep; 37(3):641-658. PubMed ID: 37258326
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Heart and Lung Transplants from HCV-Infected Donors to Uninfected Recipients.
    Woolley AE; Singh SK; Goldberg HJ; Mallidi HR; Givertz MM; Mehra MR; Coppolino A; Kusztos AE; Johnson ME; Chen K; Haddad EA; Fanikos J; Harrington DP; Camp PC; Baden LR;
    N Engl J Med; 2019 Apr; 380(17):1606-1617. PubMed ID: 30946553
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association between ezetimibe usage and hepatitis C RNA levels in uninfected kidney transplant recipients who received hepatitis C infected kidneys.
    Azhar A; Binari LA; Joglekar K; Tsujita M; Talwar M; Balaraman V; Bhalla A; Eason JD; Hall IE; Rofaiel G; Forbes RC; Shaffer D; Concepcion BP; Molnar MZ
    Clin Transplant; 2021 Dec; 35(12):e14485. PubMed ID: 34523744
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of using kidneys from hepatitis C nucleic acid test-positive donors for transplantation in hepatitis C-negative recipients.
    Kadatz M; Klarenbach S; Gill J; Gill JS
    Am J Transplant; 2018 Oct; 18(10):2457-2464. PubMed ID: 29797402
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and Safety of Sofosbuvir-Based Antiviral Therapy to Treat Hepatitis C Virus Infection After Kidney Transplantation.
    Kamar N; Marion O; Rostaing L; Cointault O; Ribes D; Lavayssière L; Esposito L; Del Bello A; Métivier S; Barange K; Izopet J; Alric L
    Am J Transplant; 2016 May; 16(5):1474-9. PubMed ID: 26587971
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Successful Treatment of Hepatitis C in Renal Transplant Recipients With Direct-Acting Antiviral Agents.
    Sawinski D; Kaur N; Ajeti A; Trofe-Clark J; Lim M; Bleicher M; Goral S; Forde KA; Bloom RD
    Am J Transplant; 2016 May; 16(5):1588-95. PubMed ID: 26604182
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatitis C-positive donor liver transplantation for hepatitis C seronegative recipients.
    Ting PS; Hamilton JP; Gurakar A; Urrunaga NH; Ma M; Glorioso J; King E; Toman LP; Wesson R; Garonzik-Wang J; Ottmann S; Philosophe B; Sulkowski M; Cameron AM; Durand CM; Chen PH
    Transpl Infect Dis; 2019 Dec; 21(6):e13194. PubMed ID: 31609520
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transplant of Kidneys From Hepatitis C Virus-Positive Donors To Hepatitis C Virus-Negative Recipients: A Retrospective Study and Systematic Review.
    Shadekejiang H; Zhu J; Wu X
    Exp Clin Transplant; 2022 Dec; 20(12):1076-1084. PubMed ID: 36718006
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transplanting Kidney Allografts from Hepatitis C Infected Donors into Hepatitis C Uninfected Recipients: Re-Thinking the Thinker Trial.
    Hussaini T; Yoshida EM
    Ann Hepatol; 2017; 16(5):702-703. PubMed ID: 28809730
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Successful Treatment With Direct-Acting Antiviral Agents of Hepatitis C in Patients With End-Stage Renal Disease and Kidney Transplant Recipients.
    Özer Etik D; Suna N; Öcal S; Selçuk H; Dağlı Ü; Çolak T; Hilmioğlu F; Boyacıoğlu AS; Haberal M
    Exp Clin Transplant; 2019 Feb; 17(1):52-58. PubMed ID: 30719954
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ultrashort direct-acting antiviral prophylaxis for human immunodeficiency virus and hepatitis C virus coinfected donor positive to human immunodeficiency virus-positive kidney transplants.
    Moinuddin I; Yakubu I; Bhati A; Morales M; Sterling RK; Gupta G
    Am J Transplant; 2024 May; 24(5):876-878. PubMed ID: 38097017
    [No Abstract]   [Full Text] [Related]  

  • 32. Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus-Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial.
    Durand CM; Bowring MG; Brown DM; Chattergoon MA; Massaccesi G; Bair N; Wesson R; Reyad A; Naqvi FF; Ostrander D; Sugarman J; Segev DL; Sulkowski M; Desai NM
    Ann Intern Med; 2018 Apr; 168(8):533-540. PubMed ID: 29507971
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ultra-short duration direct acting antiviral prophylaxis to prevent virus transmission from hepatitis C viremic donors to hepatitis C negative kidney transplant recipients.
    Gupta G; Yakubu I; Bhati CS; Zhang Y; Kang L; Patterson JA; Andrews-Joseph A; Alam A; Ferreira-Gonzalez A; Kumar D; Moinuddin IK; Kamal L; King AL; Levy M; Sharma A; Cotterell A; Reichman TW; Khan A; Kimball P; Stiltner R; Baldecchi M; Brigle N; Gehr T; Sterling RK
    Am J Transplant; 2020 Mar; 20(3):739-751. PubMed ID: 31652392
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transplantation of kidneys from HCV viremic donors to HCV viremic recipients followed by early direct acting antiviral therapy without ribavirin.
    Kapila N; Flocco G; Al Khalloufi K; Zervos XB
    J Viral Hepat; 2019 Mar; 26(3):407-409. PubMed ID: 30449062
    [No Abstract]   [Full Text] [Related]  

  • 35. Increasing Utilization and Excellent Initial Outcomes Following Liver Transplant of Hepatitis C Virus (HCV)-Viremic Donors Into HCV-Negative Recipients: Outcomes Following Liver Transplant of HCV-Viremic Donors.
    Cotter TG; Paul S; Sandıkçı B; Couri T; Bodzin AS; Little EC; Sundaram V; Charlton M
    Hepatology; 2019 Jun; 69(6):2381-2395. PubMed ID: 30706517
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of Using Kidneys From HCV-Viremic Donors for Transplantation Into HCV-Uninfected Recipients.
    Eckman MH; Woodle ES; Thakar CV; Alloway RR; Sherman KE
    Am J Kidney Dis; 2020 Jun; 75(6):857-867. PubMed ID: 32081494
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and Efficacy of Treatment of Hepatitis C in Kidney Transplant Recipients With Directly Acting Antiviral Agents.
    Lubetzky M; Chun S; Joelson A; Coco M; Kamal L; Ajaimy M; Gaglio P; Akalin E; De Boccardo G
    Transplantation; 2017 Jul; 101(7):1704-1710. PubMed ID: 28009781
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transplanting Hepatitis C Virus-Infected Versus Uninfected Kidneys Into Hepatitis C Virus-Infected Recipients: A Cost-Effectiveness Analysis.
    Eckman MH; Woodle ES; Thakar CV; Paterno F; Sherman KE
    Ann Intern Med; 2018 Aug; 169(4):214-223. PubMed ID: 29987322
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of Hepatitis C Virus Infection on Heart Transplants in the Current Era.
    Fujisaki T; Mikami T; Kuno T; Moss N; Itagaki S
    Transplantation; 2021 Nov; 105(11):2482-2489. PubMed ID: 33496557
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systematic review: hepatitis C viraemic allografts to hepatitis C-negative recipients in solid organ transplantation.
    Raasikh T; Jamali T; Flores A; Cotton RT; Ramanathan V; Tan HP; Hernaez R
    Aliment Pharmacol Ther; 2021 Sep; 54(5):571-582. PubMed ID: 34265111
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.